Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03085524 · ClinicalTrials.gov registry record
The Impact of Diabetes on REvascularization
A clinical trial of Diabetes Mellitus and Peripheral Arterial Disease, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 215
- Enrollment target
- 20
- Study locations
NCT03085524 is a study of Diabetes Mellitus and Peripheral Arterial Disease that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 215 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT03085524, a study of Diabetes Mellitus and Peripheral Arterial Disease, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 215 participants
- Enrollment target
- 20
- Study locations
Study Summary
The presence of foot symptoms at rest or tissue necrosis in patients with peripheral artery disease is a medical urgency and represents a state of critical limb ischemia (CLI) where the risk of amputation, in the absence of revascularization, is high. No trial conducted to date in peripheral revascularization has determined the effect of diabetes on mechanism of revascularization failure. Therefore, this trial represents a unique opportunity to investigate the mechanisms by which diabetes affects surgical and endovascular revascularization procedures with the long-term goal of improving outcomes in CLI.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Platelet function testing
- DIAGNOSTIC_TEST Vascular ultrasonography
Study Locations (20)
California
- Long Beach VA Medical Center - Long Beach
- Keck Medical Center of USC - Los Angeles
- San Francisco VA Medical Center - San Francisco
- University of California San Francisco Medical Center - San Francisco
Michigan
- Henry Ford Hospital - Detroit
- Michigan Vascular Center - Flint
- Michigan Heart - St. Joseph Mercy Health System - Ypsilanti
Illinois
- Loyola University Medical Center - Chicago
- Decatur Memorial Hospital - Decatur
Massachusetts
- Boston Medical Center - Boston
- University of Massachusetts Medical School - Worcester
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- University of Florida - Gainesville
Iowa
- Iowa Heart Center - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2022-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03085524
The ClinicalTrials.gov registry entry for NCT03085524 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (88% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Platelet function testing is the first listed.
NCT03085524 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Illinois.
Frequently Asked Questions
What is clinical trial NCT03085524 about?
NCT03085524 is a clinical study titled "The Impact of Diabetes on REvascularization". The presence of foot symptoms at rest or tissue necrosis in patients with peripheral artery disease is a medical urgency and represents a state of critical limb ischemia (CLI) where the risk of amputation, in the absence of revascularization, is high. No trial conducted to date in peripheral revascu...
What is the current status of trial NCT03085524?
This trial is currently completed. The enrollment target is 215 participants. The study started on 2017-08-01. Estimated completion is 2022-10-01.
What conditions does trial NCT03085524 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Peripheral Arterial Disease.
What interventions are being tested in trial NCT03085524?
The interventions under investigation include: Platelet function testing (DIAGNOSTIC_TEST), Vascular ultrasonography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03085524?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03085524 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Studies of Insulin and Diabetes
RECRUITING
-
Improving Glycemic Control With Telemedicine and Smart Insulin Pens
RECRUITING · NA
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.